Balyasny Asset Management
CBPO

Balyasny Asset Management’s China Biologic Products Holdings, Inc. CBPO Stock Holding History

Balyasny Asset Management’s Portfolio CBPO Stock Details CBPO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-7,100
Closed -$655K – 2529
2017
Q3 		$655K Buy
+7,100
New +$682K ﹤0.01% 1267

Other funds holding CBPO

Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CGI
Comgest Global Investors Paris, France $4.59B AUM 12.96% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return

Balyasny Asset Management's CBPO Position: Q4 2017 in Review

Balyasny Asset Management sold out of China Biologic Products Holdings, Inc. (CBPO) in Q4 2017, closing a stake of 7,100 shares — an estimated $655K sold.

Balyasny Asset Management first reported a position in CBPO in Q3 2017 and held it in 1 quarter. The position peaked at $655K in Q3 2017. 93 funds tracked by Wall St. Rank hold CBPO as of Q4 2017.

  • Balyasny Asset Management reported no remaining China Biologic Products Holdings, Inc. position as of Q4 2017 after selling out during the quarter.
  • Balyasny Asset Management sold 7,100 China Biologic Products Holdings, Inc. shares in Q4 2017, an estimated $655K.
  • Balyasny Asset Management first reported a position in China Biologic Products Holdings, Inc. in Q3 2017 and held it in 1 quarter.
  • Balyasny Asset Management's China Biologic Products Holdings, Inc. position peaked at $655K in Q3 2017.
  • 93 funds tracked by Wall St. Rank held China Biologic Products Holdings, Inc. as of Q4 2017.

Based on Balyasny Asset Management's 13F filing for Q4 2017, filed 14 Feb 2018.